Evaxion Biotech A/S (NASDAQ: EVAX)
$3.09
-0.0592 ( -1.88% ) 42.9K
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
Market Data
Open
$3.09
Previous close
$3.15
Volume
42.9K
Market cap
$16.99M
Day range
$2.82 - $3.23
52 week range
$2.26 - $13.82
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 2 | Mar 27, 2024 |
20-f | Annual reports | 170 | Mar 26, 2024 |
6-k | Quarterly Reports | 2 | Mar 19, 2024 |
6-k | Quarterly Reports | 3 | Mar 13, 2024 |
6-k | Quarterly Reports | 2 | Feb 29, 2024 |
6-k | Quarterly Reports | 2 | Feb 20, 2024 |
6-k | Quarterly Reports | 3 | Feb 07, 2024 |
6-k | Quarterly Reports | 3 | Feb 07, 2024 |
6-k | Quarterly Reports | 2 | Feb 06, 2024 |
6-k | Quarterly Reports | 4 | Feb 05, 2024 |